News
Article
Author(s):
This is the latest partnership for PharmaJet.
Stock.adobe.com
Immuno Cure BioTech and PharmaJet are working together on a clinical study to test the effectiveness of PharmaJet’s needle-free vaccine delivery system for Immuno Cure’s HIV therapeutic DNA vaccine.1 The study follows a successful Phase 1 study of the vaccine and will be conducted at Prince of Wales Hospital in Hong Kong SAR.
Immuno Cure’s vaccine is designed to provide patients with sustained, immune-mediated HIV-1 virological control without the need of ART.
In a press release, Immuno Cure’s CEO Dr. Xia Jin, MD, PhD, said, “We are thrilled to partner with PharmaJet on this innovative delivery approach to HIV treatment. This collaboration not only advances needle-free vaccination solutions but also accelerates the global commercialization potential for ICVAX and the vaccine's ability to transform HIV management."
In the same press release, senior vice president of corporate development at PharmaJet Dan Mallon added, “We are excited to support Immuno Cure's novel HIV-1 therapeutic vaccine program with PharmaJet's patented needle-free injection technology. PharmaJet is one of the leaders in nucleic acid-based vaccine and therapeutic delivery and we are encouraged by the potential for the Tropis intradermal delivery system to make a substantial impact for HIV patients. This partnership reflects our shared commitment to advancing innovative, patient-friendly technologies that address unmet medical needs globally."
PharmaJet has been partnering with other organizations for the use of its needle-free delivery system. The company recently announced the results of a partner trial for multiple DNA cancer vaccines at the World Vaccine Congress 2025.2 The data shows that the needle-free system can induce robust T cell response and tumor/lesion reduction in certain cancers.
In a press release issued in April, PharmaJet’s chief scientific officer Nathalie Landry said, “We are proud to support our oncology partners in their development of cancer vaccines and therapeutics with our needle-free delivery systems. Our body of data highlights how our needle-free technology can be expected to enhance vaccine immune response, and how it contributes to inducing T cell-mediated immune responses in difficult-to-treat cancer populations. We are encouraged by these results and the potential for needle-free delivery to further enhance various lines of cancer vaccines and therapies.”
In March of this year, the World Health Organization (WHO) used PharmaJet’s needle-free injection system during a polio eradication campaign in Pakistan.3 In a press release, Paul LaBarre, vice president of global business development at PharmaJet, said, “We are pleased to continue our partnership with the World Health Organization to eradicate polio. The Tropis needle-free system has been shown to be very effective and affordable in campaigns and routine immunizations, protecting nearly 12 million children against poliovirus. There is still a lot of work to do, and we are committed to achieving eradication goals so that no child suffers from paralytic polio.”
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
